Encyclopedia of Signaling Molecules

2018 Edition
| Editors: Sangdun Choi

MOZ and MORF Lysine Acetyltransferases

  • Jiang-Ping Zhang
  • Xiaoyu Du
  • Kezhi Yan
  • Xiang-Jiao Yang
Reference work entry
DOI: https://doi.org/10.1007/978-3-319-67199-4_510

Synonyms

MORF (MOZ-related factor):  KAT6B;  Lysine (K) acetyltransferase 6B;  MYST4;  Querkopf

MOZ (monocytic leukemia zinc-finger protein):  KAT6A;  Lysine (K) acetyltransferase 6A;  MYST3

Historical Background

MOZ is a founding member of the MYST (MOZ, YBF2, SAS2, and TIP60) family of lysine acetyltransferases (Borrow et al. 1996; Reifsnyder et al. 1996; reviewed in Yang and Ullah 2007). It was identified in 1996 through positional cloning of the reciprocal chromosomal t(8;16)(p11;p13) translocation with CREB-binding protein (CBP) associated with a subset of acute myeloid leukemia (AML) (Borrow et al. 1996). A few years later, the acetyltransferase activity was demonstrated and mapped to the MYST domain (Champagne et al. 2001; Kitabayashi et al. 2001a). Human MORF was identified in BLAST search against expressed sequence tag databases for additional MYST proteins (Champagne et al. 1999). Mouse Morf was also identified as Querkopf, a mutant allele causing craniofacial abnormalities (Thomas et al. 2000). MORF is highly homologous to MOZ (Fig. 1).
MOZ and MORF Lysine Acetyltransferases, Fig. 1

Schematic illustration of MOZ, MORF, and their complexes. A small region within the MYST domain of MOZ and MORF interacts with BRPF1 and paralogs, which utilize domain M for binding to ING5 and EAF6. ING5 and EAF6 form a trimeric core with BRPF1, -2 or -3. Association of ING5 with BRPF proteins promotes EAF6 interaction. The N-terminal domain of ING5 is sufficient for BRPF binding. The PHD fingers of ING5, BRPFs, MOZ, and MORF do not appear to be important for complex formation, but may mediate complex recruitment to specific chromatin domains. The bromodomain and PWWP domain of BRPF proteins may also recognize modified chromatin. Txn transcription, EN EAF6 N-terminal (adapted from Ullah et al. 2008)

Domain Organizations of MOZ and MORF

MOZ and MORF are large proteins (∼250 kDa) with multiple functional domains (Fig. 1). The MYST domain contains a C2HC nucleosome-binding domain and the histone acetyltransferase (HAT) domain. MOZ and MORF are members of the MYST family, which has five MYST members in Drosophila or humans (Fig. 1). The MYST domain is the only structural feature common to all members of this family. MOZ and MORF only show sequence similarity to the very N-terminal region and MYST domain of Enok (Enoki mushroom), the most related Drosophila protein (Scott et al. 2001). Different from Drosophila, zebra fish possesses orthologs of MOZ and MORF. Thus, different from TIP60, MOF, and HBO1, both MOZ and MORF are vertebrate specific.

Other protein domains of MOZ and MORF include an NEMM (N-terminal part of Enok, MOZ, or MORF) domain, tandem PHD (plant homeodomain linked) zinc fingers, a long acidic stretch, and a SM (serine/methionine rich) region. The C-terminal part of the NEMM domain shows some sequence similarity to histones H1 and H5. The H15-like domain was shown to promote nuclear targeting (Kitabayashi et al. 2001a). The tandem PHD fingers are similar to those of Requiem and homologs (Borrow et al. 1996; Nabirochkina et al. 2002), which may recognize methyl-lysine-containing motifs (Kouzarides 2007). Indeed, MOZ can bind directly to the trimethyl K4 of histone H3 (Paggetti et al. 2010). Both the N terminus of MOZ and MORF possess a strong transcriptional repression domain (Champagne et al. 1999). The SM domain constitutes an activation domain. The SM domain of MOZ is weaker than that of MORF, raising the interesting possibility that insertion of a PQ-stretch in the SM domain of MOZ reduces its activation potential (Champagne et al. 2001). The possession of multiple functional domains by MOZ and MORF suggests that they may regulate transcription in both acetylation-dependent and acetylation-independent manners.

MOZ and MORF Acetyltransferase Complexes

MOZ and MORF may function in the cell through their presence in the ING5 complex as the catalytic subunits (Doyon et al. 2006). ING5 is the fifth member of the novel ING (inhibitor of growth) tumor suppressor family (Soliman and Riabowol 2007). The other subunits of the MOZ/MORF complexes are EAF6 (homolog of yeast Esa1-associated factor 6) and BRPF1 (bromodomain-PHD finger protein 1) (Doyon et al. 2006). Different from MOZ and MORF alone, ING5-MOZ/MORF complexes acetylate only histone H3 at lysine 14 (Doyon et al. 2006). BRPF1 binds to the MYST domains of MOZ and MORF, stimulates acetyltransferase and coactivator activities, and bridges interaction with ING5 and EAF6 (Ullah et al. 2008). Coexpression of MOZ, BRPF1, and ING5 has synergistic effect on the Runx2 promoter. MOZ/MORF-ING5 complexes are important for DNA replication (Doyon et al. 2006).

MOZ and MORF Act as Transcriptional Coactivators of Transcription Factors

Both MOZ and MORF are widely expressed in various mouse and human tissues (Borrow et al. 1996; Champagne et al. 1999; Katsumoto et al. 2006; Thomas et al. 2006), so similar to GCN5/PCAF and p300/CBP, they may function as coactivators for many transcription factors. Many evidences have demonstrated that MOZ and MORF act as coactivators for different transcription factors such as Runxs, Hox, ETV6, PU.1, and P53; all of them play pivotal roles in different development and cellular processes.

MOZ and MORF can bind to Runx2 (runt-related transcription factor 2) through the SM domain and potentiate Runx2-dependent transcriptional activation (Pelletier et al. 2002). Runx2 plays an important role in T-cell lymphomagenesis (Pelletier et al. 2002) and is essential in controlling osteoblast differentiation and bone formation (Ducy et al. 2000; Wheeler et al. 2000). The SM domain of MORF can also bind to Runx1 (Pelletier et al. 2002). Runx1-interacting domains in MOZ include the SM-rich region and the basic domain between 312 and 664 (Kitabayashi et al. 2001a). Runx1 is essential for generation of hematopoietic stem cells (Okuda et al. 1996; Wang et al. 1996) and is important for differentiation of megakaryocytes and lymphocytes (Ichikawa et al. 2004; Growney et al. 2005).

Studies in mouse and zebra fish indicate that MOZ plays a key role in controlling HOX (homeobox) gene expression (Miller et al. 2004; Camos et al. 2006; Crump et al. 2006; Katsumoto et al. 2006; Laue et al. 2008; Voss et al. 2009), so unknown DNA-binding transcription factor may recruit MOZ to achieve this goal. In human cord blood CD34+ cells, MOZ interact with MLL (mixed lineage leukemia) that encodes a histone methyltransferase. Both are recruited to multiple HOX promoters and synergistically stimulate HOX genes expression (Paggetti et al. 2010). HOX genes encode transcription factors that are involved in embryogenesis and morphogenesis (McGinnis and Krumlauf 1992) and exert crucial functions in normal hematopoiesis (van Oostveen et al. 1999).

The ets-family transcription factor ETV6 (TEL) is essential for the establishment of adult hematopoiesis in the bone marrow (Wang et al. 1998) and is involved in the balanced chromosomal translocations in various hematological malignancies and in some soft tissue tumors (Sato et al. 1997; Rowley 1999). MOZ and MORF are able to interact with portions of ETV6 through the MYST domains (Putnik et al. 2007).

MOZ also can physically and functionally interact with PU.1, a transcription factor that is essential for maintenance of hematopoietic stem cells and development of myeloid and lymphoid lineages (Scott et al. 1994; McKercher et al. 1996; Kim et al. 2004; Iwasaki et al. 2005). In addition, MOZ forms a complex with p53 to induce p21 expression and cell cycle arrest (Rokudai et al. 2009). MOZ can also function as a coactivator of the Nrf2-MafK and NF-κB (Chan et al. 2007; Ohta et al. 2007). MORF is present in the transcriptional coactivator complex associated with the nuclear receptor peroxisome proliferator-activated receptor-α (PPARα) (Surapureddi et al. 2002).

Moz in Development

Consistent with the regulatory role of MOZ/MORF on the activities of transcription factors that are essential in different processes, studies on mutant models indicate that MOZ and MORF play key roles in hematopoiesis, skeletogenesis, neurogenesis, and other developmental processes (Thomas et al. 2000; Miller et al. 2004; Crump et al. 2006; Katsumoto et al. 2006; Merson et al. 2006; Thomas et al. 2006).

Homozygous Moz mutant mice lacking the Moz protein expression die at birth. Fetal liver hematopoietic cells from the Moz mutant fail to contribute to the hematopoietic system of recipients after transplantation and display defects in the stem cell compartment (Thomas et al. 2006). Moz-/- mice without the expression of Moz die around embryonic day 15 (E15). In Moz-/- E14.5 embryos, HSCs (hematopoietic stem cells) and progenitors are decreased, and maturation of erythroid cells is inhibited in Moz-deficient fetal liver that is due to the synergistic effects of decreased expression of c-Mpl, HoxA9, and c-Kit (Katsumoto et al. 2006). Therefore, Moz is essential for the maintenance of hematopoietic stem cells.

A mouse strain carrying a point mutation that inactivate the HAT activity of the Moz protein remain alive during all the gestation period, but about 40% of the homozygote mice die within the first 6 month. These mice exhibit significant defects in the number of HSCs and committed precursors and B-cell development defect. The reduced number of HSCs is caused by the failure of HAT-/- cells to expand. These results indicate that the HAT activity of Moz play a critical role in the proliferation and maintenance of hematopoietic precursors (Perez-Campo et al. 2009).

Studies on Moz-/- mutant mice (Thomas et al. 2006) also show that Moz is required for normal levels of H3K9 acetylation and gene expression at a large number of Hox loci and for correct body segment identity specification of 19 body segments. In addition, Moz is required for Ing5 and H3 K4 methyltransferase Mll1 recruitment to the Hox loci (Voss et al. 2009). In zebra fish, it was found that Brpf1 and Moz tightly cooperate to promote histone acetylation and maintenance of anterior Hox gene expression and determine pharyngeal segmental identities (Laue et al. 2008).

MORF in Development

Mice homozygous mutants for Querkopf fail to thrive in the postnatal period, display craniofacial abnormalities due to defects in the calvarial bones, and have defects in cerebral cortex development (Thomas et al. 2000). Homozygous mice show smaller cerebral cortex, lack of large pyramidal cells in layer V of the cortex, and have reduction in the number of GAD67-positive interneurons throughout the cortex, suggesting that Querkopf is an essential in regulating cell differentiation in the cortex (Thomas et al. 2000). Querkopf-deficient mice also display defects in adult neurogenesis in vivo. Isolated neural stem/progenitor cells exhibit decreased self-renewal capacity and reduced ability to produce differentiated neurons. Thus, Querkopf is also essential for adult neurogenesis.

Moz and Morf in Oncogenesis

MOZ fusion proteins caused by chromosome rearrangement enable the transformation of non-self-renewing myeloid progenitors into leukemia stem cells (Huntly et al. 2004). Fusion partners of MOZ include CBP (Borrow et al. 1996), CBP paralog p300 (Chaffanet et al. 2000; Kitabayashi et al. 2001b), the p300/CBP-interacting nuclear receptor coactivators TIF2 (transcription intermediary factor 2) (Carapeti et al. 1998; Liang et al. 1998), and nuclear receptor coactivators 2 (NCOA3) (Esteyries et al. 2008). MORF translocation is also associated with childhood AML or therapeutic myelodysplastic syndromes, in which the MORF gene is fused to that of CBP (Panagopoulos et al. 2001; Kojima et al. 2003). MORF gene is also disrupted in multiple cases of uterine leiomyomata. GCN5 is the fusion partner candidate (Moore et al. 2004). Deregulation of gene expression resulting from these translocations may be involved in the tumor pathogenesis. MOZ is involved in regulating cell cycle arrest in the G1 phase (Rokudai et al. 2009). DNA damage increases the level of p53-MOZ complex. In MOZ-/- mouse fibroblasts, DNA damage fails to induce the expression of p21 and G1 cell cycle arrest. MOZ-CBP inhibits p53-mediated transcription. Thus, the inhibition of p53/MOZ-mediated transcription contributes to the leukemogenesis and tumor pathogenesis (Rokudai et al. 2009).

MOZ/MORF has been shown to be coactivators of Runx genes. Runx2 functions as a novel oncogenic effector for T-cell lymphoma (Vaillant et al. 1999; Blyth et al. 2001). Runx1 is an important regulator of fetal liver hematopoiesis, and its gene is frequently rearranged in leukemia patients (Speck et al. 1999; Westendorf and Hiebert 1999). The expression levels of MORF/MOZ may affect roles of Runx proteins in the development of T-cell lymphoma and leukemogenesis. In addition, MOZ-TIF2 and MOZ-CBP stimulate the expression of macrophage colony-stimulating factor receptor (CSF1R) through the interaction with PU.1, and thus induce AML (Aikawa et al. 2010).

Summary

MOZ and MORF belong to the MYST family of histone acetyltransferase. The multifunctional domains also confer the function of transcriptional co-regulators. Thus, MOZ and MORF can regulate gene expression by acetylation-dependent and acetylation-independent manners. MOZ and MORF acetylate histone H3 at lysine 23. MOZ and MORF act as coactivator for different transcription factors such as Runxs, Hox, ETV6, PU.1, and P53; all of them play pivotal roles in different development and cellular processes. Accordingly, studies on mutant models indicate that MOZ and MORF play key roles in hematopoiesis, skeletogenesis, neurogenesis, body segment identity specification, and cell cycle control. MOZ and MORF are targets of chromosome rearrangement that are associated with leukemia and other types of tumor. Deregulation of gene expression resulting from these translocations may be involved in the tumor pathogenesis.

Notes

Acknowledgments

This research was supported by operating grants from Canadian Institutes of Health Research (CIHR) and Canadian Cancer Society (to X. J. Y.).

References

  1. Aikawa Y, Katsumoto T, Zhang P, Shima H, Shino M, Terui K, Ito E, Ohno H, Stanley ER, Singh H, et al. PU.1-mediated upregulation of CSF1R is crucial for leukemia stem cell potential induced by MOZ-TIF2. Nat Med. 2010;16:580–5.PubMedPubMedCentralCrossRefGoogle Scholar
  2. Blyth K, Terry A, Mackay N, Vaillant F, Bell M, Cameron ER, Neil JC, Stewart M. Runx2: a novel oncogenic effector revealed by in vivo complementation and retroviral tagging. Oncogene. 2001;20:295–302.PubMedCrossRefGoogle Scholar
  3. Borrow J, Stanton Jr VP, Andresen JM, Becher R, Behm FG, Chaganti RS, Civin CI, Disteche C, Dube I, Frischauf AM, et al. The translocation t(8;16)(p11;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein. Nat Genet. 1996;14:33–41.PubMedCrossRefGoogle Scholar
  4. Camos M, Esteve J, Jares P, Colomer D, Rozman M, Villamor N, Costa D, Carrio A, Nomdedeu J, Montserrat E, et al. Gene expression profiling of acute myeloid leukemia with translocation t(8;16)(p11;p13) and MYST3-CREBBP rearrangement reveals a distinctive signature with a specific pattern of HOX gene expression. Cancer Res. 2006;66:6947–54.PubMedCrossRefGoogle Scholar
  5. Carapeti M, Aguiar RC, Goldman JM, Cross NC. A novel fusion between MOZ and the nuclear receptor coactivator TIF2 in acute myeloid leukemia. Blood. 1998;91:3127–33.PubMedGoogle Scholar
  6. Chaffanet M, Gressin L, Preudhomme C, Soenen-Cornu V, Birnbaum D, Pebusque MJ. MOZ is fused to p300 in an acute monocytic leukemia with t(8;22). Genes Chromosom Cancer. 2000;28:138–44.PubMedCrossRefGoogle Scholar
  7. Champagne N, Bertos NR, Pelletier N, Wang AH, Vezmar M, Yang Y, Heng HH, Yang XJ. Identification of a human histone acetyltransferase related to monocytic leukemia zinc finger protein. J Biol Chem. 1999;274:28528–36.PubMedCrossRefGoogle Scholar
  8. Champagne N, Pelletier N, Yang XJ. The monocytic leukemia zinc finger protein MOZ is a histone acetyltransferase. Oncogene. 2001;20:404–9.PubMedCrossRefGoogle Scholar
  9. Chan EM, Chan RJ, Comer EM, Goulet 3rd RJ, Crean CD, Brown ZD, Fruehwald AM, Yang Z, Boswell HS, Nakshatri H, et al. MOZ and MOZ-CBP cooperate with NF-kappaB to activate transcription from NF-kappaB-dependent promoters. Exp Hematol. 2007;35:1782–92.PubMedCrossRefGoogle Scholar
  10. Crump JG, Swartz ME, Eberhart JK, Kimmel CB. Moz-dependent Hox expression controls segment-specific fate maps of skeletal precursors in the face. Development. 2006;133:2661–9.PubMedCrossRefGoogle Scholar
  11. Doyon Y, Cayrou C, Ullah M, Landry AJ, Cote V, Selleck W, Lane WS, Tan S, Yang XJ, Cote J. ING tumor suppressor proteins are critical regulators of chromatin acetylation required for genome expression and perpetuation. Mol Cell. 2006;21:51–64.PubMedCrossRefGoogle Scholar
  12. Ducy P, Schinke T, Karsenty G. The osteoblast: a sophisticated fibroblast under central surveillance. Science. 2000;289:1501–4.PubMedCrossRefGoogle Scholar
  13. Esteyries S, Perot C, Adelaide J, Imbert M, Lagarde A, Pautas C, Olschwang S, Birnbaum D, Chaffanet M, Mozziconacci MJ. NCOA3, a new fusion partner for MOZ/MYST3 in M5 acute myeloid leukemia. Leukemia. 2008;22:663–5.PubMedCrossRefGoogle Scholar
  14. Growney JD, Shigematsu H, Li Z, Lee BH, Adelsperger J, Rowan R, Curley DP, Kutok JL, Akashi K, Williams IR, et al. Loss of Runx1 perturbs adult hematopoiesis and is associated with a myeloproliferative phenotype. Blood. 2005;106:494–504.PubMedPubMedCentralCrossRefGoogle Scholar
  15. Huntly BJ, Shigematsu H, Deguchi K, Lee BH, Mizuno S, Duclos N, Rowan R, Amaral S, Curley D, Williams IR, et al. MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell. 2004;6:587–96.PubMedCrossRefGoogle Scholar
  16. Ichikawa M, Asai T, Saito T, Seo S, Yamazaki I, Yamagata T, Mitani K, Chiba S, Ogawa S, Kurokawa M, et al. AML-1 is required for megakaryocytic maturation and lymphocytic differentiation, but not for maintenance of hematopoietic stem cells in adult hematopoiesis. Nat Med. 2004;10:299–304.PubMedCrossRefGoogle Scholar
  17. Iwasaki H, Somoza C, Shigematsu H, Duprez EA, Iwasaki-Arai J, Mizuno S, Arinobu Y, Geary K, Zhang P, Dayaram T, et al. Distinctive and indispensable roles of PU.1 in maintenance of hematopoietic stem cells and their differentiation. Blood. 2005;106:1590–600.PubMedPubMedCentralCrossRefGoogle Scholar
  18. Katsumoto T, Aikawa Y, Iwama A, Ueda S, Ichikawa H, Ochiya T, Kitabayashi I. MOZ is essential for maintenance of hematopoietic stem cells. Genes Dev. 2006;20:1321–30.PubMedPubMedCentralCrossRefGoogle Scholar
  19. Kim HG, de Guzman CG, Swindle CS, Cotta CV, Gartland L, Scott EW, Klug CA. The ETS family transcription factor PU.1 is necessary for the maintenance of fetal liver hematopoietic stem cells. Blood. 2004;104:3894–900.PubMedCrossRefGoogle Scholar
  20. Kitabayashi I, Aikawa Y, Nguyen LA, Yokoyama A, Ohki M. Activation of AML1-mediated transcription by MOZ and inhibition by the MOZ-CBP fusion protein. EMBO J. 2001a;20:7184–96.PubMedPubMedCentralCrossRefGoogle Scholar
  21. Kitabayashi I, Aikawa Y, Yokoyama A, Hosoda F, Nagai M, Kakazu N, Abe T, Ohki M. Fusion of MOZ and p300 histone acetyltransferases in acute monocytic leukemia with a t(8;22)(p11;q13) chromosome translocation. Leukemia. 2001b;15:89–94.PubMedCrossRefGoogle Scholar
  22. Kojima K, Kaneda K, Yoshida C, Dansako H, Fujii N, Yano T, Shinagawa K, Yasukawa M, Fujita S, Tanimoto M. A novel fusion variant of the MORF and CBP genes detected in therapy-related myelodysplastic syndrome with t(10;16)(q22;p13). Br J Haematol. 2003;120:271–3.PubMedCrossRefGoogle Scholar
  23. Kouzarides T. Chromatin modifications and their function. Cell. 2007;128:693–705.PubMedCrossRefGoogle Scholar
  24. Laue K, Daujat S, Crump JG, Plaster N, Roehl HH, Kimmel CB, Schneider R, Hammerschmidt M. The multidomain protein Brpf1 binds histones and is required for Hox gene expression and segmental identity. Development. 2008;135:1935–46.PubMedPubMedCentralCrossRefGoogle Scholar
  25. Liang J, Prouty L, Williams BJ, Dayton MA, Blanchard KL. Acute mixed lineage leukemia with an inv(8)(p11q13) resulting in fusion of the genes for MOZ and TIF2. Blood. 1998;92:2118–22.PubMedGoogle Scholar
  26. McGinnis W, Krumlauf R. Homeobox genes and axial patterning. Cell. 1992;68:283–302.PubMedCrossRefGoogle Scholar
  27. McKercher SR, Torbett BE, Anderson KL, Henkel GW, Vestal DJ, Baribault H, Klemsz M, Feeney AJ, Wu GE, Paige CJ, et al. Targeted disruption of the PU.1 gene results in multiple hematopoietic abnormalities. EMBO J. 1996;15:5647–58.PubMedPubMedCentralGoogle Scholar
  28. Merson TD, Dixon MP, Collin C, Rietze RL, Bartlett PF, Thomas T, Voss AK. The transcriptional coactivator Querkopf controls adult neurogenesis. J Neurosci. 2006;26:11359–70.PubMedCrossRefGoogle Scholar
  29. Miller CT, Maves L, Kimmel CB. Moz regulates Hox expression and pharyngeal segmental identity in zebrafish. Development. 2004;131:2443–61.PubMedCrossRefGoogle Scholar
  30. Moore SD, Herrick SR, Ince TA, Kleinman MS, Dal Cin P, Morton CC, Quade BJ. Uterine leiomyomata with t(10;17) disrupt the histone acetyltransferase MORF. Cancer Res. 2004;64:5570–7.PubMedCrossRefGoogle Scholar
  31. Nabirochkina E, Simonova OB, Mertsalov IB, Kulikova DA, Ladigina NG, Korochkin LI, Buchman VL. Expression pattern of dd4, a sole member of the d4 family of transcription factors in Drosophila melanogaster. Mech Dev. 2002;114:119–23.PubMedCrossRefGoogle Scholar
  32. Ohta K, Ohigashi M, Naganawa A, Ikeda H, Sakai M, Nishikawa J, Imagawa M, Osada S, Nishihara T. Histone acetyltransferase MOZ acts as a co-activator of Nrf2-MafK and induces tumour marker gene expression during hepatocarcinogenesis. Biochem J. 2007;402:559–66.PubMedPubMedCentralCrossRefGoogle Scholar
  33. Okuda T, van Deursen J, Hiebert SW, Grosveld G, Downing JR. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell. 1996;84:321–30.PubMedCrossRefGoogle Scholar
  34. Paggetti J, Largeot A, Aucagne R, Jacquel A, Lagrange B, Yang XJ, Solary E, Bastie JN, Delva L. Crosstalk between leukemia-associated proteins MOZ and MLL regulates HOX gene expression in human cord blood CD34+ cells. Oncogene. 2010;29:5019–31.PubMedCrossRefGoogle Scholar
  35. Panagopoulos I, Fioretos T, Isaksson M, Samuelsson U, Billstrom R, Strombeck B, Mitelman F, Johansson B. Fusion of the MORF and CBP genes in acute myeloid leukemia with the t(10;16)(q22;p13). Hum Mol Genet. 2001;10:395–404.PubMedCrossRefGoogle Scholar
  36. Pelletier N, Champagne N, Stifani S, Yang XJ. MOZ and MORF histone acetyltransferases interact with the Runt-domain transcription factor Runx2. Oncogene. 2002;21:2729–40.PubMedCrossRefGoogle Scholar
  37. Perez-Campo FM, Borrow J, Kouskoff V, Lacaud G. The histone acetyl transferase activity of monocytic leukemia zinc finger is critical for the proliferation of hematopoietic precursors. Blood. 2009;113:4866–74.PubMedPubMedCentralCrossRefGoogle Scholar
  38. Putnik J, Zhang CD, Archangelo LF, Tizazu B, Bartels S, Kickstein M, Greif PA, Bohlander SK. The interaction of ETV6 (TEL) and TIP60 requires a functional histone acetyltransferase domain in TIP60. Biochim Biophys Acta. 2007;1772:1211–24.PubMedCrossRefGoogle Scholar
  39. Reifsnyder C, Lowell J, Clarke A, Pillus L. Yeast SAS silencing genes and human genes associated with AML and HIV-1 Tat interactions are homologous with acetyltransferases. Nat Genet. 1996;14:42–9.PubMedCrossRefGoogle Scholar
  40. Rokudai S, Aikawa Y, Tagata Y, Tsuchida N, Taya Y, Kitabayashi I. Monocytic leukemia zinc finger (MOZ) interacts with p53 to induce p21 expression and cell-cycle arrest. J Biol Chem. 2009;284:237–44.PubMedCrossRefGoogle Scholar
  41. Rowley JD. The role of chromosome translocations in leukemogenesis. Semin Hematol. 1999;36:59–72.PubMedGoogle Scholar
  42. Sato Y, Bohlander SK, Kobayashi H, Reshmi S, Suto Y, Davis EM, Espinosa R, Hoopes R, Montgomery KT, Kucherlapati RS, et al. Heterogeneity in the breakpoints in balanced rearrangements involving band 12p13 in hematologic malignancies identified by fluorescence in situ hybridization: TEL (ETV6 ) is involved in only one half. Blood. 1997;90:4886–93.PubMedGoogle Scholar
  43. Scott EW, Simon MC, Anastasi J, Singh H. Requirement of transcription factor PU.1 in the development of multiple hematopoietic lineages. Science. 1994;265:1573–7.PubMedCrossRefGoogle Scholar
  44. Scott EK, Lee T, Luo L. Enok encodes a Drosophila putative histone acetyltransferase required for mushroom body neuroblast proliferation. Curr Biol. 2001;11:99–104.PubMedCrossRefGoogle Scholar
  45. Soliman MA, Riabowol K. After a decade of study-ING, a PHD for a versatile family of proteins. Trends Biochem Sci. 2007;32:509–19.PubMedCrossRefGoogle Scholar
  46. Speck NA, Stacy T, Wang Q, North T, Gu TL, Miller J, Binder M, Marin-Padilla M. Core-binding factor: a central player in hematopoiesis and leukemia. Cancer Res. 1999;59:1789s–93s.PubMedGoogle Scholar
  47. Surapureddi S, Yu S, Bu H, Hashimoto T, Yeldandi AV, Kashireddy P, Cherkaoui-Malki M, Qi C, Zhu YJ, Rao MS, et al. Identification of a transcriptionally active peroxisome proliferator-activated receptor alpha -interacting cofactor complex in rat liver and characterization of PRIC285 as a coactivator. Proc Natl Acad Sci U S A. 2002;99:11836–41.PubMedPubMedCentralCrossRefGoogle Scholar
  48. Thomas T, Voss AK, Chowdhury K, Gruss P. Querkopf, a MYST family histone acetyltransferase, is required for normal cerebral cortex development. Development. 2000;127:2537–48.PubMedGoogle Scholar
  49. Thomas T, Corcoran LM, Gugasyan R, Dixon MP, Brodnicki T, Nutt SL, Metcalf D, Voss AK. Monocytic leukemia zinc finger protein is essential for the development of long-term reconstituting hematopoietic stem cells. Genes Dev. 2006;20:1175–86.PubMedPubMedCentralCrossRefGoogle Scholar
  50. Ullah M, Pelletier N, Xiao L, Zhao SP, Wang K, Degerny C, Tahmasebi S, Cayrou C, Doyon Y, Goh SL, et al. Molecular architecture of quartet MOZ/MORF histone acetyltransferase complexes. Mol Cell Biol. 2008;28:6828–43.PubMedPubMedCentralCrossRefGoogle Scholar
  51. Vaillant F, Blyth K, Terry A, Bell M, Cameron ER, Neil J, Stewart M. A full-length Cbfa1 gene product perturbs T-cell development and promotes lymphomagenesis in synergy with myc. Oncogene. 1999;18:7124–34.PubMedCrossRefGoogle Scholar
  52. van Oostveen J, Bijl J, Raaphorst F, Walboomers J, Meijer C. The role of homeobox genes in normal hematopoiesis and hematological malignancies. Leukemia. 1999;13:1675–90.PubMedCrossRefGoogle Scholar
  53. Voss AK, Collin C, Dixon MP, Thomas T. Moz and retinoic acid coordinately regulate H3K9 acetylation, Hox gene expression, and segment identity. Dev Cell. 2009;17:674–86.PubMedCrossRefGoogle Scholar
  54. Wang Q, Stacy T, Binder M, Marin-Padilla M, Sharpe AH, Speck NA. Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. Proc Natl Acad Sci U S A. 1996;93:3444–9.PubMedPubMedCentralCrossRefGoogle Scholar
  55. Wang LC, Swat W, Fujiwara Y, Davidson L, Visvader J, Kuo F, Alt FW, Gilliland DG, Golub TR, Orkin SH. The TEL/ETV6 gene is required specifically for hematopoiesis in the bone marrow. Genes Dev. 1998;12:2392–402.PubMedPubMedCentralCrossRefGoogle Scholar
  56. Westendorf JJ, Hiebert SW. Mammalian runt-domain proteins and their roles in hematopoiesis, osteogenesis, and leukemia. J Cell Biochem. 1999;Suppl 32–33:51–8.PubMedCrossRefGoogle Scholar
  57. Wheeler JC, Shigesada K, Gergen JP, Ito Y. Mechanisms of transcriptional regulation by Runt domain proteins. Semin Cell Dev Biol. 2000;11:369–75.PubMedCrossRefGoogle Scholar
  58. Yang XJ, Ullah M. MOZ and MORF, two large MYSTic HATs in normal and cancer stem cells. Oncogene. 2007;26:5408–19.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  • Jiang-Ping Zhang
    • 1
    • 2
  • Xiaoyu Du
    • 1
    • 2
  • Kezhi Yan
    • 1
    • 2
  • Xiang-Jiao Yang
    • 1
    • 2
  1. 1.The Rosalind and Morris Goodman Cancer Research Center and Department of BiochemistryMcGill UniversityMontréalCanada
  2. 2.Department of MedicineMcGill University Health CenterMontréalCanada